How the New PCOS Name PMOS Aims to Break Decades of Stigma Surrounding Women's Health

Polycystic Ovary Syndrome (PCOS) has been renamed PMOS (polyendocrine metabolic ovarian syndrome) following over a decade of research and collaboration among 56 patient and professional organizations worldwide. The new name, announced in *The Lancet*, was developed by experts at Monash University and Oulu University to better capture the condition’s endocrine, metabolic, and ovarian complexities, which extend beyond reproductive issues. The old term, PCOS, misled patients and clinicians by emphasizing ovarian cysts, obscuring its broader impact on hormonal balance, insulin resistance, infertility, and psychological health. Professor Helena Teede, director of Monash University’s Monash Centre for Health Research & Implementation, led the effort, emphasizing that the rename prioritizes patient benefit, scientific accuracy, and stigma reduction. PMOS centers on three core features: endocrine dysfunction, metabolic effects, and ovarian involvement, aligning with current medical understanding. Symptoms like irregular periods, acne, weight changes, and infertility have often been dismissed as personal issues rather than medical concerns, delaying diagnoses and treatment. Dr. Alla Vash-Margita of Yale University noted the old name fueled stigma, as many assumed patients had large cysts, which is rarely the case. The rename aims to shift perceptions globally, improving clinical practice and research. Researchers stress that PMOS better reflects the condition’s systemic nature, encouraging healthcare providers to take patients’ experiences seriously. The change marks a turning point in addressing decades of misunderstanding and misdiagnosis for millions affected by the disorder.